Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

BRCA1/2 Mutation

University Health Network, TorontoSmall moleculePhase 2/3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the BRCA1/2 Mutation cohort.

Asset / SponsorPhaseRating
Olaparib
VA Office of Research and Development
Phase 3BB
Carboplatin
VA Office of Research and Development
Phase 2BB
Veliparib
AbbVie
Phase 2BB
Letrozole
UNICANCER
Phase 3BB
Metformin
Alliance for Clinical Trials in Oncology
Phase 3B

View all 26 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →